1-(3-丙氧基溴)-3-溴苯 | 37142-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-丙氧基溴)-3-溴苯
• 英文名称: 1-(3-bromopropoxy)-3-chlorobenzene
• 英文别名: 3-(3-chlorophenoxy)propyl bromide；3-(m-chlorophenoxy)propyl bromide；(3-bromo-propyl)-(3-chloro-phenyl)-ether；(3-Brom-propyl)-(3-chlor-phenyl)-aether
• CAS: 37142-46-4
• 化学式: C₉H₁₀BrClO
• mdl: MFCD00596672
• 分子量: 249.535
• InChiKey: MVKLHPFBHSJVLA-UHFFFAOYSA-N

物化性质

• 沸点：
  139-148 °C (8 mmHg)
• 密度：
  1.454±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  <p>遵照规定使用和储存，则不会分解。</p>

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn,Xi
• 安全说明：
  S23,S26,S37/39
• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2909309090

SDS

Name:	1-(3-Bromopropoxy)-3-chlorobenzene 96% Material Safety Data Sheet
Synonym:
CAS:	37142-46-4

Section 1 - Chemical Product MSDS Name:1-(3-Bromopropoxy)-3-chlorobenzene 96% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37142-46-4	1-(3-Bromopropoxy)-3-chlorobenzene	96%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37142-46-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: stench
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 139 - 148 deg C @8mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >150 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H10BrClO
Molecular Weight: 249.53

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37142-46-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(3-Bromopropoxy)-3-chlorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AVIATION REGULATED LIQUID, N.O.S.*
Hazard Class: 9
UN Number: 3334
Packing Group:
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 37142-46-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37142-46-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37142-46-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-丙氧基溴)-3-溴苯 在 sodium ethanolate 、 三氟乙酸 、 sodium iodide 作用下， 以 二氯甲烷 为溶剂， 反应 31.0h， 生成 3-[3-(3-Chlorophenoxy)propyl]-4-hydroxy-2H-1-benzopyran-2-one
  参考文献：
  名称：

  Lunney; Hagen; Domagala, Journal of Medicinal Chemistry, 1994, vol. 37, # 17, p. 2664 - 2677

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯苯酚 、 1,3-二溴丙烷 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 8.0h， 生成 1-(3-丙氧基溴)-3-溴苯
  参考文献：
  名称：

  新型二氢-1,3,5-三嗪作为人DHFR抑制剂的设计，合成，对接研究和生物学评估

  摘要：

  在分子对接作用的基础上，设计合成了一系列带有杂原子螺环的二氢-1,3,5-三嗪衍生物，并对其生物学活性进行了评价。化合物A2，A5，B1和B3显示有效的人二氢叶酸还原酶（hDHFR）抑制活性，相对于参考药物甲氨蝶呤（MTX），IC 50值为7.46 nM，3.72 nM，6.46 nM，4.08 nM。从分子对接的结果可以得出结论，由柔性残基Phe31变形产生的构象空间有利于螺环的结合，而将杂原子插入螺环中可能会增加结合亲和力。有24种化合物具有对多种肿瘤细胞系（HCT116，A549，HL-60，HepG2和MDA-MB-231）具有广谱抗增殖活性的化合物50个值，范围从0.79至0.001μM。在人肺泡基底上皮细胞系A549异种移植模型中确定化合物A2的体内抗肿瘤活性。这项研究提供了具有高抑制活性的靶向hDHFR的新型抗癌药，并具有新型分子支架与hDHFR的结合模式。这为进一步开发新型hDHFR抑制剂提供了有力的支持。

  DOI：

  10.1016/j.ejmech.2016.11.010

文献信息

• [EN] OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS<br/>[FR] OXADIAZOLONES EN TANT QU'INHIBITEURS DE CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018096159A1

  公开（公告）日：2018-05-31

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  该发明涉及式(I)的化合物及其药用可接受的盐。此外，本发明涉及制备方法和使用式(I)的化合物的方法，以及含有这种化合物的药物组合物。这些化合物可能在治疗由TRPA1介导的疾病和症状，如疼痛方面有用。
• Muscarinic acetylcholine receptor antagonists
  申请人：Laine I. Damane

  公开号：US20070185155A1

  公开（公告）日：2007-08-09

  Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

  提供了肌肽乙酰胆碱受体拮抗剂及其使用方法。
• Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy
  作者：Jack A. Terrett、Huifen Chen、Daniel G. Shore、Elisia Villemure、Robin Larouche-Gauthier、Martin Déry、Francis Beaumier、Léa Constantineau-Forget、Chantal Grand-Maître、Luce Lépissier、Stéphane Ciblat、Claudio Sturino、Yong Chen、Baihua Hu、Aijun Lu、Yunli Wang、Andrew P. Cridland、Stuart I. Ward、David H. Hackos、Rebecca M. Reese、Shannon D. Shields、Jun Chen、Alessia Balestrini、Lorena Riol-Blanco、Wyne P. Lee、John Liu、Eric Suto、Xiumin Wu、Juan Zhang、Justin Q. Ly、Hank La、Kevin Johnson、Matt Baumgardner、Kang-Jye Chou、Alexis Rohou、Lionel Rougé、Brian S. Safina、Steven Magnuson、Matthew Volgraf

  DOI：10.1021/acs.jmedchem.0c02023

  日期：2021.4.8

  ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable

  瞬时受体电位锚蛋白 1 (TRPA1) 是一种非选择性钙渗透性离子通道，在初级感觉神经元中高度表达，充当外源性和内源性刺激的多模式传感器，由于其在神经性疼痛中的作用，作为抑制靶点引起了广泛的兴趣和呼吸道疾病。在此，我们描述了一系列有效的、选择性的、口服生物可利用的 TRPA1 小分子拮抗剂的优化，从而发现了一种新型的基于四氢呋喃的接头。鉴于理化性质的平衡和大鼠 AITC 诱导的疼痛测定中强大的体内靶点参与，化合物20被进展到豚鼠卵清蛋白哮喘模型中，在该模型中它表现出显着的剂量依赖性炎症反应减少。此外，通过低温电子显微镜以3 Å的分辨率确定了与化合物21结合的TRPA1通道的结构，揭示了此类拮抗剂的结合位点和作用机制。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005061457A1

  公开（公告）日：2005-07-07

  Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.

  描述了一种具有一般式(I)和(II)的新型替代哌啶化合物，其中详细说明了取代基定义。这些化合物特别适用作为肾素抑制剂，并且具有很高的效力。
• Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ
  作者：Zheng Li、Zongtao Zhou、Fengjian Deng、Yuyi Li、Danjun Zhang、Luyong Zhang

  DOI：10.1016/j.ejmech.2018.09.071

  日期：2018.11

  of metabolic syndrome such as type 2 diabetes. Based on the hypothesis that the dual agonists of PPARs and FFA1 would act as insulin sensitizers and secretagogues by simultaneous activation of PPARs and FFA1, we developed the design strategy to obtain dual PPARs/FFA1 agonist by hybrid FFA1 agonist 1 with PPARδ agonist 2 in consideration of their structural similarity. As expected, systematic exploration

  游离脂肪酸受体1（FFA1）和过氧化物酶体增殖物激活受体（PPARs）作为治疗代谢综合征（如2型糖尿病）的有效靶标引起了人们的兴趣。基于该假设，即PPARs的和FFA1的双重激动剂将作为胰岛素敏化剂和分泌由PPARs的和FFA1的同时激活，我们开发了设计策略通过混合FFA1以获得双PPARs的/ FFA1激动剂激动剂1与PPARδ激动剂2在考虑它们的结构相似性。不出所料，系统探索结构-活性关系和分子模型可导致发现铅化合物15，一种泛激动剂，在FFA1，PPARγ和PPARδ之间具有相对平衡的活性。剂量反应关系研究表明，泛激动剂15以剂量依赖的方式抑制了血糖水平的波动。在ob / ob小鼠接受5天治疗期间，泛激动剂15（100 mg / kg）表现出持续的降血糖作用，甚至接近最先进的FFA1激动剂（TAK-875，40 mg / kg），这可能是由于它的泛PPARs / FFA1活性可同时调